Incyte Corporation

This early-stage study tests a new drug, INCA033989, given alone or with another drug (ruxolitinib) in 225 adults with myeloproliferative neoplasms, a group of rare blood cancers. The main goals are to check safety, find the best dose, and see how well the drug works. Participant…

This program provides expanded access to axatilimab for one patient with chronic graft versus host disease (GVHD), a condition where donor immune cells attack the patient's body after a stem cell transplant. The treatment aims to control the disease, but patients typically need o…

This study tests a drug called tafasitamab in adults with two autoimmune blood disorders: immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The goal is to see if the drug can safely improve blood cell counts and reduce symptoms. About 56 participants wil…

This study tests a drug called axatilimab for Chinese patients with chronic graft-versus-host disease (cGVHD) that has not improved with standard treatments. cGVHD is a complication after a stem cell transplant where the donor cells attack the patient's body. The goal is to see i…

This early-phase study tests a new drug called INCA33890 in about 408 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their g…

This study tests two different drug combinations to prevent graft-versus-host disease (GVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. About 572 adults with blood cancers will receive either tacrolimus/methotrexate/ru…

This study tests a new drug, INCB123667, against standard chemotherapy in people with a type of ovarian cancer that no longer responds to platinum-based treatments. The cancer must have high levels of a protein called cyclin E1. About 466 adults will take part to see if the new d…

This early-stage trial tests a new drug, INCA033989, given alone or with another drug (ruxolitinib) in about 290 adults with myeloproliferative neoplasms, a group of blood cancers. The main goals are to check safety, find the best dose, and see if it helps control the disease. Pa…

This program offers early access to a drug called retifanlimab, combined with standard chemotherapy, for adults with advanced squamous cell carcinoma of the anal canal who cannot join other clinical trials. The goal is to control the disease and improve outcomes. Participants mus…

This early-phase study tests a new drug called INCB123667, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard care. The main goals are to check safety, find the right dose, and see if the drug can help control the …

This early-phase study tests a new drug, INCA036873, in adults with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The main goal is to check the drug's safety and find the right dose. About 280 participants will take part across multip…

This early-phase study tests a new drug called INCB161734, alone or with other cancer treatments, in people with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check safety and find the right dose. About 710 adults whose cancer has worsened a…

This expanded access program provides itacitinib, an experimental drug, to one patient with STAT1 gain-of-function disease who also has aplastic anemia. The goal is to control the overactive immune system and manage the disease. This is not a cure, and the patient will likely nee…

This study tests whether adding the experimental drug INCB161734 to standard chemotherapy helps people with a certain genetic form of advanced pancreatic cancer (KRAS G12D mutation) live longer and keep the cancer from growing. About 588 adults who have not had prior treatment fo…

This study tests an experimental drug called INCB123667 in people with a specific type of ovarian cancer that no longer responds to platinum chemotherapy. About 160 participants with high-grade serous ovarian cancer and high levels of a protein called cyclin E1 will receive the d…

This study tests whether adding the experimental drug INCA33890 to standard chemotherapy and bevacizumab helps people with metastatic colorectal cancer that is microsatellite stable (a type that doesn't respond well to immunotherapy). About 700 adults who have not had prior treat…

This study provides ongoing treatment with tafasitamab for up to 25 adults with blood cancers who are already benefiting from the drug in an earlier study. The main goal is to monitor safety and side effects over time. Participants must be tolerating the treatment well and have s…

This study tests an experimental drug called INCB000928 in people with fibrodysplasia ossificans progressiva (FOP), a rare genetic condition where soft tissues turn into bone. About 98 participants aged 2 and older will receive either the drug or a placebo to see if it reduces ne…

This study tests a cream called ruxolitinib in children aged 6 to 12 with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the cream can safely bring back color, especially on the face. About 250 children will take part, and they mus…

This early-stage study tests a new drug, INCA035784, in 120 adults with certain blood cancers (myeloproliferative neoplasms). The main goal is to check safety and find the right dose. Participants must have specific genetic mutations and have tried other treatments before.

This study tests whether adding the drug axatilimab to standard steroid treatment helps people with moderate to severe chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. About 240 participants aged 12 and older will receive either axati…

This study offers continued treatment with povorcitinib for up to 600 adults with hidradenitis suppurativa who completed a prior trial and saw benefit. The main goal is to track side effects over time, with a secondary focus on reducing skin abscesses, nodules, and tunnels. Parti…

This early-phase study tests a new drug called INCB160058 in adults with myeloproliferative neoplasms, a group of rare blood cancers. The main goal is to check the drug's safety and how the body processes it. About 186 participants will receive the drug to find the right dose and…

This study tests a cream called ruxolitinib in 180 children with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the cream can safely bring back color, especially on the face. Participants will apply the cream daily for several mont…

This early-stage study tests an experimental drug, INCA036978, in about 218 adults with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check the drug's safety and find the best dose, either alone or with standard treatment. Participants must have a l…

This study tests an experimental drug called povorcitinib in 240 adults with moderate to severe asthma that is not well controlled by current treatments. Participants will receive one of three doses of the drug or a placebo for 24 weeks. The main goal is to see if the drug improv…

This study tests a new medicine called axatilimab against the best current treatments for children with chronic graft-versus-host disease (cGVHD), a serious condition that can occur after a stem cell transplant. About 60 children aged 2 to 17 who have already tried at least two o…

This study tests a cream called ruxolitinib for people with mild to moderate hidradenitis suppurativa (HS), a skin condition that causes painful, boil-like lumps. About 550 adults with HS for at least 6 months will use either the cream or a placebo for several weeks. The main goa…

This study tests an experimental drug called povorcitinib in 40 teenagers (ages 12–17) with moderate to severe hidradenitis suppurativa, a condition that causes painful boils under the skin. The goal is to see if the drug is safe and can reduce symptoms like abscesses and inflamm…

This study tests whether a cream called ruxolitinib can reduce the painful bumps and abscesses caused by hidradenitis suppurativa (HS). About 550 adults with mild-to-moderate HS will apply the cream or a placebo twice daily for several weeks. The main goal is to see if at least 7…

This early-stage study tests a cream called ruxolitinib in 24 adults and teens with hidradenitis suppurativa, a chronic skin condition causing painful lumps. The main goal is to check safety and how much of the drug gets into the blood. Participants must have moderate to severe d…

This study tests a cream called ruxolitinib for children and teens (ages 6 to 17) with moderate eczema. The cream is applied to the skin to reduce itching, redness, and rash. About 240 participants will use either the cream or a placebo to see if it works and is safe.

This study follows 1,500 adults who recently had a stem cell transplant to learn more about chronic Graft-Versus-Host Disease (cGVHD), a common complication. Researchers will track how often cGVHD occurs, how severe it is, and what resources patients need to manage it. No new tre…

This study looks at how taking food or other medicines (itraconazole and carbamazepine) changes the way a new drug called INCB123667 moves through the body. It involves 51 healthy adults aged 19 to 55. The goal is to gather safety and drug interaction information, not to treat an…

This study looks at how two drugs—povorcitinib (taken by mouth) and ruxolitinib cream (applied to the skin)—travel through the body and skin of 24 healthy adults aged 18 to 65. Researchers use a special device to sample fluid from the skin and take blood tests to measure drug lev…

This study looks at pregnant women with mild to moderate eczema (atopic dermatitis) who use ruxolitinib cream and compares their babies' health to those who don't use the cream. Researchers want to see if the cream affects the risk of birth defects. About 958 women aged 15-50 wil…

This study compares pregnancy and infant outcomes in women with atopic dermatitis (eczema) who used ruxolitinib cream during pregnancy versus those who used topical corticosteroids. Researchers will analyze health records from over 5,600 women to see if there are differences in b…